Main Logo
+17162654855
[email protected]

Exploring European Pharmaceutical Contract Manufacturing Industry Market Disruption and Innovation

European Pharmaceutical Contract Manufacturing Industry by Service Type (Active P, Finished, Secondary Packaging), by Europe (United Kingdom, Germany, France, Italy, Spain, Netherlands, Belgium, Sweden, Norway, Poland, Denmark) Forecast 2026-2034

Base Year: 2025
197 Pages
Main Logo

Exploring European Pharmaceutical Contract Manufacturing Industry Market Disruption and Innovation

About Precision Market View

Precision Market View offers precise market research, industry intelligence, and data analysis for healthcare, manufacturing, technology, and energy. Our reports provide the clarity you need to make informed decisions and drive growth.

Our team combines primary research, advanced analytics, and industry expertise to deliver actionable intelligence. We offer syndicated reports, custom research, and consulting services tailored to your business needs.

At Precision Market View, we are committed to quality, transparency, and client satisfaction. Every report is rigorously validated to ensure accuracy and relevance. Our global perspective and local expertise help you understand both the big picture and the finer details of your market.

Stay informed with Precision Market View. Subscribe to our newsletter for the latest updates and research highlights, and follow us on social media for real-time insights.

Precision Market View – Clarity for Your Strategic Decisions.

Geographic Coverage of European Pharmaceutical Contract Manufacturing Industry

Higher Coverage
Lower Coverage
No Coverage

European Pharmaceutical Contract Manufacturing Industry REPORT HIGHLIGHTS

AspectsDetails
Study Period 2020-2034
Base Year 2025
Estimated Year 2026
Forecast Period2026-2034
Historical Period2020-2025
Growth RateCAGR of 8.2% from 2020-2034
Segmentation
    • By Service Type
      • Active P
      • Finished
        • Solid Dose Formulation
        • Liquid Dose Formulation
        • Injectable Dose Formulation
      • Secondary Packaging
  • By Geography
    • Europe
      • United Kingdom
      • Germany
      • France
      • Italy
      • Spain
      • Netherlands
      • Belgium
      • Sweden
      • Norway
      • Poland
      • Denmark

Table of Contents

  1. 1. Introduction
    • 1.1. Research Scope
    • 1.2. Market Segmentation
    • 1.3. Research Objective
    • 1.4. Definitions and Assumptions
  2. 2. Executive Summary
    • 2.1. Market Snapshot
  3. 3. Market Dynamics
    • 3.1. Market Drivers
    • 3.2. Market Restrains
    • 3.3. Market Trends
    • 3.4. Market Opportunities
  4. 4. Market Factor Analysis
    • 4.1. Porters Five Forces
      • 4.1.1. Bargaining Power of Suppliers
      • 4.1.2. Bargaining Power of Buyers
      • 4.1.3. Threat of New Entrants
      • 4.1.4. Threat of Substitutes
      • 4.1.5. Competitive Rivalry
    • 4.2. PESTEL analysis
    • 4.3. BCG Analysis
      • 4.3.1. Stars (High Growth, High Market Share)
      • 4.3.2. Cash Cows (Low Growth, High Market Share)
      • 4.3.3. Question Mark (High Growth, Low Market Share)
      • 4.3.4. Dogs (Low Growth, Low Market Share)
    • 4.4. Ansoff Matrix Analysis
    • 4.5. Supply Chain Analysis
    • 4.6. Regulatory Landscape
    • 4.7. Current Market Potential and Opportunity Assessment (TAM–SAM–SOM Framework)
    • 4.8. PMV Analyst Note
  5. 5. Market Analysis, Insights and Forecast 2021-2033
    • 5.1. Market Analysis, Insights and Forecast - by Service Type
      • 5.1.1. Active P
      • 5.1.2. Finished
        • 5.1.2.1. Solid Dose Formulation
        • 5.1.2.2. Liquid Dose Formulation
        • 5.1.2.3. Injectable Dose Formulation
      • 5.1.3. Secondary Packaging
    • 5.2. Market Analysis, Insights and Forecast - by Region
      • 5.2.1. Europe
  6. 6. European Pharmaceutical Contract Manufacturing Industry Analysis, Insights and Forecast, 2021-2033
    • 6.1. Market Analysis, Insights and Forecast - by Service Type
      • 6.1.1. Active P
      • 6.1.2. Finished
        • 6.1.2.1. Solid Dose Formulation
        • 6.1.2.2. Liquid Dose Formulation
        • 6.1.2.3. Injectable Dose Formulation
      • 6.1.3. Secondary Packaging
  7. 7. Competitive Analysis
      • 7.1. Company Profiles
        • 7.1.1 Fareva Holdings SA
          • 7.1.1.1. Company Overview
          • 7.1.1.2. Products
          • 7.1.1.3. Company Financials
          • 7.1.1.4. SWOT Analysis
        • 7.1.2 Famar SA
          • 7.1.2.1. Company Overview
          • 7.1.2.2. Products
          • 7.1.2.3. Company Financials
          • 7.1.2.4. SWOT Analysis
        • 7.1.3 Cenexi - Laboratoires Thissen SA
          • 7.1.3.1. Company Overview
          • 7.1.3.2. Products
          • 7.1.3.3. Company Financials
          • 7.1.3.4. SWOT Analysis
        • 7.1.4 Almac Group*List Not Exhaustive
          • 7.1.4.1. Company Overview
          • 7.1.4.2. Products
          • 7.1.4.3. Company Financials
          • 7.1.4.4. SWOT Analysis
        • 7.1.5 Lonza Group
          • 7.1.5.1. Company Overview
          • 7.1.5.2. Products
          • 7.1.5.3. Company Financials
          • 7.1.5.4. SWOT Analysis
        • 7.1.6 Aenova Group
          • 7.1.6.1. Company Overview
          • 7.1.6.2. Products
          • 7.1.6.3. Company Financials
          • 7.1.6.4. SWOT Analysis
        • 7.1.7 Boehringer Ingelheim Group
          • 7.1.7.1. Company Overview
          • 7.1.7.2. Products
          • 7.1.7.3. Company Financials
          • 7.1.7.4. SWOT Analysis
        • 7.1.8 Recipharm AB
          • 7.1.8.1. Company Overview
          • 7.1.8.2. Products
          • 7.1.8.3. Company Financials
          • 7.1.8.4. SWOT Analysis
      • 7.2. Market Entropy
        • 7.2.1 Company's Key Areas Served
        • 7.2.2 Recent Developments
      • 7.3. Company Market Share Analysis 2025
        • 7.3.1 Top 5 Companies Market Share Analysis
        • 7.3.2 Top 3 Companies Market Share Analysis
    • 7.4. List of Potential Customers
  8. 8. Research Methodology

    List of Figures

    1. Figure 1: European Pharmaceutical Contract Manufacturing Industry Revenue Breakdown (billion, %) by Product 2025 & 2033
    2. Figure 2: European Pharmaceutical Contract Manufacturing Industry Share (%) by Company 2025

    List of Tables

    1. Table 1: European Pharmaceutical Contract Manufacturing Industry Revenue billion Forecast, by Service Type 2020 & 2033
    2. Table 2: European Pharmaceutical Contract Manufacturing Industry Revenue billion Forecast, by Region 2020 & 2033
    3. Table 3: European Pharmaceutical Contract Manufacturing Industry Revenue billion Forecast, by Service Type 2020 & 2033
    4. Table 4: European Pharmaceutical Contract Manufacturing Industry Revenue billion Forecast, by Country 2020 & 2033
    5. Table 5: United Kingdom European Pharmaceutical Contract Manufacturing Industry Revenue (billion) Forecast, by Application 2020 & 2033
    6. Table 6: Germany European Pharmaceutical Contract Manufacturing Industry Revenue (billion) Forecast, by Application 2020 & 2033
    7. Table 7: France European Pharmaceutical Contract Manufacturing Industry Revenue (billion) Forecast, by Application 2020 & 2033
    8. Table 8: Italy European Pharmaceutical Contract Manufacturing Industry Revenue (billion) Forecast, by Application 2020 & 2033
    9. Table 9: Spain European Pharmaceutical Contract Manufacturing Industry Revenue (billion) Forecast, by Application 2020 & 2033
    10. Table 10: Netherlands European Pharmaceutical Contract Manufacturing Industry Revenue (billion) Forecast, by Application 2020 & 2033
    11. Table 11: Belgium European Pharmaceutical Contract Manufacturing Industry Revenue (billion) Forecast, by Application 2020 & 2033
    12. Table 12: Sweden European Pharmaceutical Contract Manufacturing Industry Revenue (billion) Forecast, by Application 2020 & 2033
    13. Table 13: Norway European Pharmaceutical Contract Manufacturing Industry Revenue (billion) Forecast, by Application 2020 & 2033
    14. Table 14: Poland European Pharmaceutical Contract Manufacturing Industry Revenue (billion) Forecast, by Application 2020 & 2033
    15. Table 15: Denmark European Pharmaceutical Contract Manufacturing Industry Revenue (billion) Forecast, by Application 2020 & 2033

    Frequently Asked Questions

    1. What is the projected Compound Annual Growth Rate (CAGR) of the European Pharmaceutical Contract Manufacturing Industry?

    The projected CAGR is approximately 8.2%.

    2. Which companies are prominent players in the European Pharmaceutical Contract Manufacturing Industry?

    Key companies in the market include Fareva Holdings SA, Famar SA, Cenexi - Laboratoires Thissen SA, Almac Group*List Not Exhaustive, Lonza Group, Aenova Group, Boehringer Ingelheim Group, Recipharm AB.

    3. What are the main segments of the European Pharmaceutical Contract Manufacturing Industry?

    The market segments include Service Type.

    4. Can you provide details about the market size?

    The market size is estimated to be USD 209.9 billion as of 2022.

    5. What are some drivers contributing to market growth?

    Increasing Outsourcing Volume by Pharmaceutical Companies; Increasing Investment in R&D.

    6. What are the notable trends driving market growth?

    Rising Investment in R&D will Drive The Market Growth.

    7. Are there any restraints impacting market growth?

    Increasing Lead Time and Logistics Costs; Stringent Regulatory Requirements; Capacity Utilization Issues Affecting the Profitability of CMOs.

    8. Can you provide examples of recent developments in the market?

    March 2022: MorphoSys sacked US R&D to consolidate work in Germany, taking USD 254 million in charges. MorphoSys axed its early pipeline and U.S. R&D work that came with the USD 1.7 billion purchase of Constellation Pharmaceuticals, meaning a more than USD 250 million impairment charge as the German pharma shifted the focus home.

    9. What pricing options are available for accessing the report?

    Pricing options include single-user, multi-user, and enterprise licenses priced at USD 3800, USD 4500, and USD 5800 respectively.

    10. Is the market size provided in terms of value or volume?

    The market size is provided in terms of value, measured in billion.

    11. Are there any specific market keywords associated with the report?

    Yes, the market keyword associated with the report is "European Pharmaceutical Contract Manufacturing Industry," which aids in identifying and referencing the specific market segment covered.

    12. How do I determine which pricing option suits my needs best?

    The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.

    13. Are there any additional resources or data provided in the European Pharmaceutical Contract Manufacturing Industry report?

    While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.

    14. How can I stay updated on further developments or reports in the European Pharmaceutical Contract Manufacturing Industry?

    To stay informed about further developments, trends, and reports in the European Pharmaceutical Contract Manufacturing Industry, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.

    Methodology

    Step 1 - Identification of Relevant Samples Size from Population Database

    Step Chart
    Bar Chart
    Method Chart

    Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)

    Approach Chart
    Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segments, product, and application.

    Note*: In applicable scenarios

    Step 3 - Data Sources

    Primary Research

    • Web Analytics
    • Survey Reports
    • Research Institute
    • Latest Research Reports
    • Opinion Leaders

    Secondary Research

    • Annual Reports
    • White Paper
    • Latest Press Release
    • Industry Association
    • Paid Database
    • Investor Presentations
    Analyst Chart

    Step 4 - Data Triangulation

    Involves using different sources of information in order to increase the validity of a study

    These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.

    Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.

    During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence

    Additionally, after gathering mixed and scattered data from a wide range of sources, data is triangulated and correlated to come up with estimated figures which are further validated through primary mediums or industry experts, opinion leaders.